

## PRESS RELEASE

# Hansa Biopharma to host conference call to provide half year results for January-June 2022 and Business Update

**Lund, Sweden June 30, 2022** Hansa Biopharma AB (Nasdaq Stockholm: HNSA) will publish its interim report for January-June 2022 at 8:00 CET on July 19, 2022. All interested parties are invited to participate in a telephone conference, which will include a presentation of the interim results and a business update, on the same date at 14:00 CET/8:00am EST. The event will be hosted by Hansa Biopharma's CEO, Søren Tulstrup, and CFO, Donato Spota, and the presentation will be held in English.

Slides used in the presentation will be live on the company website during the call under "Events & Presentations" and will also be made available online after the call. [Link to presentation](#)

To participate in the telephone conference, please use the dial-in details provided below:

Sweden: +46 10 884 80 16

United Kingdom: +44 020 3936 2999

United States: +1 646 664 1960

The webcast will be available on <https://streams.eventcdn.net/hansa/q2-2022/>

Participant access code: 729818

### Updated Calendar and Events 2022

July 19, 2022	Half year 2022 report
Aug 9, 2022	BTIG Biotechnology Conference 2022, New York
Aug 10, 2022	Canaccord Annual Growth Conference, Boston
Aug 11-12, 2022	Kempen US non-deal road show
Aug 18, 2022	Penserpodden "Focus on autoimmunity" (virtual)
Aug 31, 2022	Redeye Late Stage Life Science conference, Stockholm
Sept 7, 2022	Pareto annual Healthcare Conference 2022, Stockholm
Sept 7-8, 2022	Citi's 17th Annual BioPharma Conference, Boston
Sept 12-14, 2022	MorganStanley Global Healthcare Conference, New York
Sept 20, 2022	Redeye Afterwork presentation, Gothenburg
Sept 21, 2022	Redeye Lunch presentation, Stockholm
Sept 26, 2022	Aktiespararna Aktiedagen, Lund
Oct 20, 2022	Interim Report for January-September 2022
Nov 23, 2022	Økonomisk Ugebrev Life Science Conference, Copenhagen
Nov 24, 2022	Redeye Life Science Day, Stockholm
Dec 1, 2022	Erik Penser Banks Temadag - Health Care, Stockholm

### **About Hansa Biopharma**

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions. Hansa has developed a

first-in-class immunoglobulin G (IgG) antibody cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa has a rich and expanding research and development program, based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden and has operations in Europe and the U.S. The Company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at <https://hansabiopharma.com>.

For more information:

Klaus Sindahl, *Head of Investor Relations*

**M:** +46 (0) 709-298 269

**E:** [klaus.sindahl@hansabiopharma.com](mailto:klaus.sindahl@hansabiopharma.com)

Katja Margell, *Head of Corporate Communications*

**M:** +46 (0) 768-198 326

**E:** [katja.margell@hansabiopharma.com](mailto:katja.margell@hansabiopharma.com)